On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financing to ...

TAK-721 is one of 12 "Wave1" pipeline drug candidates that have been held up by Takeda as potential blockbuster products, because they are either best-in-class or first-in-class therapies. The ...

C4 photosynthesis serves as a prominent example of convergent evolution in complex traits. Here, the authors construct chromosome-scale genome assemblies for five Flaveria species and investigate ...

Visit a quote page and your recently viewed tickers will be displayed here.

Feb. 27, 2025 — Researchers examined dozens of bird species in museum collections looking for differences in the feathers and bodies between birds that can fly and birds that can't. They found ...

3382.T Seven & i Holdings Co., Ltd.